Module

Mechanisms of Resistance to Anti-HBV Agents

Source: Clinical Strategies for Preventing Drug Resistance in Chronic Hepatitis B Infection

Mechanisms of Resistance to Anti-HBV Agents

Faculty:

Maria Buti, MD

CREDIT INFORMATION

Release Date: 01/28/09

Expiration Date: 01/27/10

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 0.9 Nursing contact hours

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the mechanisms by which HBV may develop resistance to antiviral therapy
Explain how viral mutations that confer resistance to one anti-HBV agent may also cause cross-resistance to other agents
Describe clinical strategies that may minimize the risk of developing drug-resistant HBV

Topics covered include:

Introduction to HBV Resistance
HBV Life Cycle
Differences and Similarities of FDA-Approved Oral Anti-HBV Agents
HBV Resistance Mutations and Pathways
Antiviral Activity vs Genetic Barrier to Resistance
Virologic Monitoring and Testing for HBV Resistance
Consequences of Drug-Resistant HBV in Treatment-Naive Patients
Summary and Conclusion

Abstract

Click here to view abstract

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.